Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Refametinib (Primary) ; Sorafenib (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Bayer

    • Most Recent Events

    • 07 Dec 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top